FT : Planet Labs launches $2.8bn deal in latest space Spac

Planet Labs launches $2.8bn deal in latest space Spac
Earth imaging company hopes to capitalise on demand for data to measure environmental and social goals

Planet Labs, the Earth imaging business whose fleet of small satellites captures daily data about how the globe is changing, has struck a $2.8bn deal to become a public company.

San Francisco-based Planet will merge with dMY Technology Group IV, a special purpose acquisition company listed on NYSE, raising net proceeds of $434m, after transaction expenses and paying down debt.

The deal is expected to give the combined business an equity value of about $2.8bn when it closes in the fourth quarter of 2021. The deal includes a $200m private investment in public equity, or Pipe financing, led by clients of BlackRock, as well as Google, Salesforce founder Marc Benioff’s Time Ventures, and energy group Koch.

“Planet is ready to go out into the world and the world really needs Planet,” said Will Marshall, co-founder and chief executive, as it hopes to capitalise on growing demand from governments and companies for data to measure environmental and social goals.

Founded in 2010 by three former Nasa scientists, Planet now operates about 200 satellites, some of them barely larger than a shoe box, carrying an array of cameras and other sensors.

Together, these satellites capture a new scan of the Earth’s entire landmass every day, generating data that can be used to track farms, natural disasters, ships and planes, deforestation, and infrastructure.

Planet is the latest Spac related to space, after recent multibillion-dollar deals involving Rocket Lab, which builds rockets, and Spire, another maker of small satellites to track Earth data, were launched in March.

One of the earliest of the current flurry of Spac transactions saw Virgin Galactic go public via a merger with Social Capital Hedosophia in late 2019. Virgin Galactic’s stock has doubled so far this year to a market value of $11bn.

Planet Labs will also become one of the first public benefit corporations to list through a Spac, after the debut of AppHarvest, an agriculture technology company, earlier this year.

Public benefit corporations, sometimes known as a B Corp, are intended to allow the company to pursue a social or environmental mission that may come at the expense of financial results. Planet, which will become a PBC once it goes public, has not yet disclosed its mission.

A dual-class share structure will allow Marshall and his co-founder Robbie Schingler to retain control of the business after it goes public.

Planet’s revenues grew 18 per cent to $113m last year, from more than 600 customers. It projects growth to accelerate thanks to the infusion of cash from going public, as it builds out its sales and marketing. It recently hired Kevin Weil, a former Instagram and Twitter executive, as its head of product and business, to help improve its software and make it easier for new kinds of customers to use.

“We are fully a data business at this point, not a satellite business,” said Marshall, likening Planet’s products to a “Bloomberg terminal for Earth data”.

The company generates most of its revenues from clients in the public sector, defence and intelligence groups, agricultural companies and mapping providers, including Google, which sold its satellite photography unit Terra Bella to Planet in 2017.

In an investor presentation, Planet reported a net loss of $127m in the financial year ending in January 2021 and forecasts that it will not become profitable on an adjusted ebitda basis until fiscal 2025.

Planet will be dMY Technology’s fourth Spac deal. The investment group is led by Niccolo De Masi, a former executive at mobile and gaming companies, and Harry You, a veteran of enterprise technology and professional services companies such as EMC, Accenture and Oracle.

As a private company, Planet had raised about $380m from investors including DFJ and Founders Fund.

>>> US Gapping down

Gapping down

News:

  • IDYA -8.8% (stock offering)
  • EFC -3.9% (prices 6 mln shares of common stock at $18.22 per share)
  • GSKY -1.3% (announces multi-year expansion of relationship with Electric & Gas Industries Assn)
  • LGIH -1.2% (June home closings)
  • AES -1% (concluded that a pre-tax impairment charge in the range of ~$500-550 million)

Analyst comments:

  • WTER -3.4% (downgraded to Sell from Hold at Canaccord Genuity)
  • MAS -1.6% (downgraded to Underweight from Neutral at JP Morgan)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • IMMR +10.5% (sees Q2 EPS and revs above consensus), SGH +5.4%, SAND +1.4% (provides Q2 operational update), MSM +1.3%

Other news:

  • ONCS +28.7% (announces clinical trial collaboration and supply agreement with MRK)
  • SBTX +25.1% (announces a clinical supply agreement with Regeneron (REGN) for Libtayo)
  • BHVN +11.5% (reported $93 million in net product revenue from sales of NURTEC ODT in the second quarter of 2021)
  • XBIT +10.7% (declares extraordinary cash dividend of ~$2.50/sh)
  • USAS +8.9% (signed an agreement with the Mexican Ministries of Economy, Interior and Labour committing to a reopening at the Cosalá Operations shut for over 17 months by an illegal blockade)
  • SEEL +5.9% (reports preliminary findings supporting advancement of SLS-004 program into additional preclinical studies of Parkinson's Disease)
  • BFRA +3.9% (seeks IPO in the USA)
  • ELYS +3.5% (to acquire U.S. Bookmaking)
  • WPRT +3% (Westport Fuel Systems, TUPY, and AVL to collaborate in demonstration of world's most efficient hydrogen-fueled internal combustion engine)
  • UUUU +2.3% (Energy Fuels and Neo Performance Materials announce contract signing and launch of commercial shipments of rare earth product to Europe in emerging U.S.-based rare earth supply chain)
  • ATHN +2.3% (announces business combination with Heliogen)
  • ELOX +2.1% (enrolls sufficient number of patients to assess biological activity of ELX-02)
  • DMYQ +1.9% (Planet to become publicly traded company through merger with dMY IV)
  • CFMS +1.9% (settles patent litigation with Wright Medical)
  • STLD +1.7% (authorizes an additional $1 bln share repurchase program)
  • STAR +1.1% (to explore market interest for its net lease assets)

Analyst comments:

  • CCXI +3.1% (upgraded to Buy from Hold at Stifel)
  • ATI +1.4% (upgraded to Neutral from Underperform at BofA Securities)

WSJ : Covid-19 Vaccine-Related Blood Clots Linked to Amino Acids in New Study

Covid-19 Vaccine-Related Blood Clots Linked to Amino Acids in New Study
Canadian researchers zero in on molecular details of antibody clusters following AstraZeneca shots

Canadian researchers say they have pinpointed a handful of amino acids targeted by key antibodies in the blood of some people who received AstraZeneca PLC’s AZN -1.46% Covid-19 vaccine, offering fresh clues to what causes rare blood clots associated with the shot.

The peer-reviewed findings, by a team of researchers from McMaster University in Ontario, were published online Wednesday by the science journal Nature. They could help doctors rapidly test for and treat the unusual clotting, arising from an immune-driven mix of coagulation and loss of platelets that stop bleeding.

The Canadian study analyzed blood samples from AstraZeneca vaccine recipients and builds on recent research done in Europe and elsewhere into the infrequent blood clots linked to the vaccine. Health officials are monitoring the rare side effects balanced with the vaccines’ proven value in fighting Covid-19. The blood clotting, which some scientists have named vaccine-induced immune thrombotic thrombocytopenia, or VITT, has also been linked to Johnson & Johnson’s Covid-19 shot, though incidents have occurred less frequently with that shot than with AstraZeneca.

Though rare, the condition has proven deadly in more than 170 adults post-vaccination in the U.K., Europe and U.S., according to government tallies. Many were younger adults who appeared healthy before vaccination, researchers and drug regulators say.

The companies have said they are undertaking further research to understand the issues and believe the vaccines’ benefits outweigh the risks. Health and government officials have said that the benefits of both vaccines generally outweigh their risks but recommend warnings about the potential risks.

Mortimer Poncz, pediatric-hematology division chief at the Children’s Hospital of Philadelphia, who wasn’t involved in the study, said the findings could help doctors rapidly identify VITT and get researchers closer to understanding what causes it. Another VITT researcher, Andreas Greinacher, professor of transfusion medicine at Germany’s Greifswald University Clinic, called the findings “highly interesting” as a new clue to vaccine-induced clotting that could improve treatment.

Scientists say research about Covid-19 vaccines could influence the safety of shots and treatments for other uses. Mass inoculations have provided a rare chance to study side effects that might go unnoticed in smaller vaccination drives.

Rare reports of blood clots first surfaced in early March among people in Europe who had received the vaccine developed by AstraZeneca and the University of Oxford. Since then, the U.K., Canada, Australia and countries in Europe and globally have limited use of the vaccine to older adults, with some countries declining to use the shot at all. Sometimes-deadly blood clotting has also surfaced among people in the U.S. and Europe who have received the J&J shot.

AstraZeneca, with more than 600 million doses distributed globally, remains an important vaccine, particularly for countries lacking access to more-expensive shots, but isn’t authorized for use in the U.S.

Researchers are racing to understand the rare combination of low blood platelets and clots and their connection to the vaccine in the hopes of rapid diagnosis and treatment and ultimately clot prevention—possibly by altering the shots’ makeup.

VITT has occurred in 1 to 2 people per 100,000 first doses of the AstraZeneca shot in the U.K., with cases more common in people under 50. The total number of cases after first or second doses in the U.K. was 395 through June 23, of roughly 45.2 million doses administered. Of the 395, 70 people have died.

European officials said this month that they have seen 479 potential cases of VITT out of 51.4 million AstraZeneca vaccinations, or just under 1 per 100,000 vaccinations. Far fewer potential cases—21 out of 7 million vaccinations, or about 0.30 per 100,000 people—followed J&J vaccinations in Europe. Of those cases, 100 deaths occurred after AstraZeneca vaccination and four after Johnson & Johnson, European regulators said.

U.S. health officials said in late June that they have identified 38 confirmed cases of the blood-clotting syndrome out of more than 12.3 million people who received the J&J vaccine, correlating to a frequency of about 0.31 in 100,000. The Centers for Disease Control and Prevention said in May that three cases had been fatal and evidence “suggests a plausible causal association” between the combination of low platelets and clotting and the vaccine. The CDC didn’t respond to requests for comment.

Both shots are so-called viral-vector vaccines, which use altered cold viruses to ferry genetic material into human cells instructing them to create Covid-19 spike proteins. That action spurs the immune system to create antibodies and defensive white blood cells that prime the body for a protective response against Covid-19.

But in rare cases, vaccinated people have experienced an autoimmune reaction in which antibodies bind with unusual strength to a blood component called platelet factor 4, or PF4, forming distinct clusters resembling a bunch of grapes. This so-called immune complex, a molecular formation in the blood, activates more platelets, “like putting a match to gasoline,” said John Kelton, an author of the Nature paper and researcher at McMaster University. He is involved in testing blood from people across Canada who develop blood clots after Covid-19 vaccination.

The process accelerates, he and other researchers say, triggering simultaneous bleeding and clotting, sometimes in the brain, stomach and other areas that can in rare cases be deadly. “We think these antibodies are incredible amplifiers, in a bad way, of the normal coagulation system,” says Dr. Kelton, who has been studying clotting effects of the blood-thinning drug heparin since the 1980s.

For the Nature article, he and fellow researchers analyzed blood from five people aged 35 to 72 who developed VITT after a single dose of the AstraZeneca vaccine. They compared the platelet and clotting responses to observations from 10 people who had suffered heparin-induced thrombocytopenia, or HIT, and 10 healthy people.

Using methods developed in part to study HIT, they mapped out where the VITT antibodies clung to the PF4. The antibodies reliably targeted eight surface amino acids, a fraction of PF4’s total.

“That’s where the forest fire starts,” said Ishac Nazy, another McMaster University researcher and an author of the Nature study. “These amino acids are super important to VITT but not to HIT.”

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • ONCS +35.1%, IMMR +11.8%, XBIT +6.9%, DMYQ +6%, SGH +5.2%, BFRA +3.9%, ELOX +3.6%, RDS.A +1.4%, SAND +1.4%, STAR +1.1%, HUYA +0.8%, SVRA +0.7%, GVA +0.7%
  • Gapping down:
    • IDYA -7.6%, EFC -3.8%, KRA -3.3%, GSKY -1.3%, WBT -1.2%, LGIH -1.2%, MKTX -1%, AES -1%, AON -0.6%, UUUU -0.5%

>>> Europe : Brokers Upgrades & Downgrades - 7th of July 2021 V2(+)

>>> Up
* Adidas Raised to Buy at HSBC; PT 360 euros
* Bluefield Solar Income Raised to Buy at Stifel
* Bossard Raised to Add at Baader Helvea; PT 330 Swiss francs
* Johnson Matthey Raised to Hold at Panmure Gordon; PT 3,039 pence
* Kone Raised to Sector Perform at RBC; PT 70 euros
* LeadDesk Raised to Buy at Inderes; PT 27 euros
* Oxford Biomedica Raised to Buy at Panmure Gordon; PT 1,479 pence
* SAP Raised to Buy at BofA; PT 150 euros (+°
* Sartorius Stedim Biotech Raised to Buy at SocGen; PT 486 euros

>>> Down
* Knorr-Bremse Cut to Equal-Weight at Morgan Stanley; PT 105 euros
* Morrison Cut to Hold at Berenberg; PT 254 pence
* TietoEVRY Cut to Neutral at Goldman; PT 29 euros
* Tomra Cut to Hold at Danske Bank Markets; PT 485 kroner (+)

>>> Initiation
* Calliditas Therapeutics Rated New Buy at SEB Equities
* Capital & Counties Rated New Buy at Berenberg; PT 200 pence
* Catena Rated New Neutral at JPMorgan; PT 500 kronor
* Dufry Reinstated Hold at Stifel; PT 63 Swiss francs
* Evonik Remains at Hold at SocGen; PT 30 Euros
* Horizonte Minerals Rated New Outperform at BMO; PT 12 pence
* Lanxess Remains Buy at SocGen; PT 74 euros
* Linc Rated New Hold at SEB Equities; PT 100 kronor
* Shaftesbury Rated New Buy at Berenberg; PT 725 pence
* Trifork Holding Rated New Hold at Danske Bank Markets (+)
* WDP Rated New Overweight at JPMorgan; PT 38 euros

>>> Call
* Berenberg Bullish on Outlook for London West End Landlords
* DWS, Schroders Flows Seen Strong; Ashmore, Jupiter Weaker: Citi (+)
* Elevator Market Growth Seen Moderating, Kone Upgraded: RBC
* Fingerprint Cards Hires Jefferies, Carnegie for Strategic Review
* SAP Double-Upgraded at BofA on Accelerating Cloud Momentum (+)
* Tesla Seen Facing Greater Scrutiny From China: Morgan Stanley

>>> Stoxx 600 Pre-Market Indications

  • BP (BPE5 TH) +1.8%
  • Shell (R6C TH) +1.4%
    • Shell Plans Additional Shareholder Distributions in 2H of 2021
  • SES (SES TH) +1.3%
  • SAP (SAP TH) +1.3%
    • SAP Raised to Buy at BofA; PT 150 euros
  • Alstom (AOMD TH) +1.2%
  • EDF (E2F TH) +1.1%
    • EDF Boosts FY Ebitda Forecast
  • VW (VOW3 TH) +1%
    • Renault’s EV Outlook Is an ‘Electropop‘ vs. a Resounding Bang
  • Adidas (ADS TH) +1%
    • Adidas Raised to Buy at HSBC; PT 360 euros
  • Deutsche Bank (DBK TH) +0.8%
  • Qiagen (QIA TH) -0.9%
  • AstraZeneca (ZEG TH) -1.1%
  • MorphoSys (MOR TH) -1.1%
  • Prosus (1TY TH) -1.6%
    • Down $823 Billion, China Tech Firm Selloff May Be Far From Over

>>> TradeGate Pre-Market Indications

DAX:
  • SAP (SAP TH) +1.2%
    • SAP Raised to Buy at BofA; PT 150 euros
  • HeidelbergCement (HEI TH) +1.1%
  • VW (VOW3 TH) +1%
    • Volkswagen Seeks to Sell Stake in Electrify America: Reuters
  • Adidas (ADS TH) +0.8%
    • Adidas Raised to Buy at HSBC; PT 360 euros
  • Deutsche Bank (DBK TH) +0.6%
MDAX:
  • K+S (SDF TH) +1.1%
  • Nordex (NDX1 TH) +1%
    • Nordex Gets 923MW Final Order From Acciona Energia in Australia
  • Shop Apotheke (SAE TH) +1%
  • Porsche SE (PAH3 TH) +0.9%
  • Thyssenkrupp (TKA TH) +0.7%
  • Telefonica Deutschland (O2D TH) -1%
SDAX:
  • ElringKlinger (ZIL2 TH) +1.1%
  • Schaeffler (SHA TH) +1.1%
  • SGL (SGL TH) +1%
  • Kloeckner (KCO TH) +0.9%
  • SAF-Holland SE (SFQ TH) +0.7%
  • Borussia Dortmund (BVB TH) -1.2%